Accueil   Diary - News   All news Poxel Presents Imeglimin Japanese Phase 1 Results

Poxel Presents Imeglimin Japanese Phase 1 Results

Poxel Presents Imeglimin Japanese Phase 1 Results and Mechanistic Data at the 9th Scientific Meeting of the Asian Association for the Study of Diabetes in Japan

 

  • Phase 1 data in Japanese subjects demonstrated Imeglimin was safe, well tolerated and exhibited a similar pharmacokinetic profile to what was observed in Caucasian subjects

  • Mechanistic data shows Imeglimin’s benefit on beta cell protection and details its unique insulin secretion pathway in response to glucose

 

Lyon, France, May 22, 2017 – POXEL SA (Euronext – POXEL - FR0012432516), a biopharmaceutical company focused on the development of innovative treatments for metabolic disorders, including type 2 diabetes, announced today the presentation of a comprehensive summary of the Phase 1 data of Imeglimin in Japanese subjects (healthy volunteers) and additional preclinical mechanistic data on Imeglimin’s unique mechanism of action in insulin secretion in response to glucose. The data were presented in two oral presentations at the 9th Scientific Meeting of the Asian Association for the Study of Diabetes (AASD) in Nagoya, Japan. Imeglimin has completed Phase 1 and Phase 2 development in approximately 1,200 patients and subjects in the U.S., EU and Japan and is ready for Phase 3 development.

 

 

Read the press release

 

 

By continuing your navigation on our site, you accept the use of cookies and the collection of your data and personal information by Lyonbiopôle, for the purposes of measuring the traffic on the website, to provide statistics and to offer you adapted content to your centers of interest. To exercise your rights of access, rectification, opposition, deletion and portability, in accordance with the General Data Protection Regulation (EU 2016/679), you are informed that you can send your request to dpo@lyonbiopole.com. More details are available by clicking here I agree